<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04727606</url>
  </required_header>
  <id_info>
    <org_study_id>20.259</org_study_id>
    <nct_id>NCT04727606</nct_id>
  </id_info>
  <brief_title>Research Project: Pilot Study on Oral Urea Use in Patients at High Risk of Kidney Stone Recurrence</brief_title>
  <acronym>Ure-Na</acronym>
  <official_title>Research Project: Pilot Study on Oral Urea Use in Patients at High Risk of Kidney Stone Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In clinical practice, many patients are not able to modify their habits to achieve a high&#xD;
      level of diuresis and fluid intake and therefore are at an elevated risk for stone&#xD;
      recurrence.&#xD;
&#xD;
      The investigators think that Ure-Na (osmotic agent) taking could help to increase urine&#xD;
      volume and decrease urine concentration, which would be of benefit in the prevention of&#xD;
      kidney stones.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in urine output at 1 week and 1 Month</measure>
    <time_frame>1 week and 1 month</time_frame>
    <description>variation in 24-hour diuresis and urine biochemistry</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Kidney Stone</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study provides for a single group, which will be its own control (pre/post intervention study). Participants in the study will receive Oral Urea (Ure-Na) treatment at a dose of 30 grams per day (2 x 15 gram pouches per day) for 1 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ure-Na</intervention_name>
    <description>Participants in the study will receive Oral Urea (Ure-Na) treatment at a dose of 30 grams per day (2 x 15 gram pouches per day)&#xD;
Treatment will continue for approximately 1 month.</description>
    <arm_group_label>Open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 60 years of age&#xD;
&#xD;
          -  High risk for recurrence (1 or more of) Bilateral or complex stones, Recurrent stones,&#xD;
             Family history (1st degree relative), Non-calcium stones, Solitary kidney or&#xD;
             anatomical abnormality, Nephrocalcinosis, Systemic disease with risk of stones&#xD;
             (tubular acidosis, cystinuria, etc.)&#xD;
&#xD;
          -  Diuresis &lt; 1.8 L/24 hours despite recommendations from physicians and/or nutritionist&#xD;
             at the kidney stone clinic (as documented in the previous 6 months)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient does not meet 1 of the 3 inclusion criteria&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Lack of understanding about the protocol and effects of Ure-Na&#xD;
&#xD;
          -  Expected inability to adequately increase fluid intake on Ure-Na&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Bhojani Naeem, MD</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>14069</phone_ext>
      <email>naeem.bhojani@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Dion M, Ankawi G, Chew B, Paterson R, Sultan N, Hoddinott P, Razvi H. CUA guideline on the evaluation and medical management of the kidney stone patient - 2016 update. Can Urol Assoc J. 2016 Nov-Dec;10(11-12):E347-E358. doi: 10.5489/cuaj.4218. Epub 2016 Nov 10.</citation>
    <PMID>28096919</PMID>
  </reference>
  <reference>
    <citation>Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol. 1996 Mar;155(3):839-43.</citation>
    <PMID>8583588</PMID>
  </reference>
  <reference>
    <citation>Soupart A, Coffernils M, Couturier B, Gankam-Kengne F, Decaux G. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH. Clin J Am Soc Nephrol. 2012 May;7(5):742-7. doi: 10.2215/CJN.06990711. Epub 2012 Mar 8.</citation>
    <PMID>22403276</PMID>
  </reference>
  <reference>
    <citation>Berl T. Impact of solute intake on urine flow and water excretion. J Am Soc Nephrol. 2008 Jun;19(6):1076-8. doi: 10.1681/ASN.2007091042. Epub 2008 Mar 12.</citation>
    <PMID>18337482</PMID>
  </reference>
  <reference>
    <citation>Decaux G, Brimioulle S, Genette F, Mockel J. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea. Am J Med. 1980 Jul;69(1):99-106.</citation>
    <PMID>7386514</PMID>
  </reference>
  <reference>
    <citation>Verbalis JG, Baldwin EF, Neish PN, Robinson AG. Effect of protein intake and urea on sodium excretion during inappropriate antidiuresis in rats. Metabolism. 1988 Jan;37(1):46-54.</citation>
    <PMID>3336285</PMID>
  </reference>
  <reference>
    <citation>Nayan M, Elkoushy MA, Andonian S. Variations between two 24-hour urine collections in patients presenting to a tertiary stone clinic. Can Urol Assoc J. 2012 Feb;6(1):30-3. doi: 10.5489/cuaj.11131.</citation>
    <PMID>22396364</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

